OTCMKTS:AFFY Affymax (AFFY) Stock Forecast, Price & News $0.0042 0.00 (0.00%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$0.0042▼$0.004250-Day Range N/A52-Week Range$0.00▼$0.04VolumeN/AAverage Volume666 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesShort InterestProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesShort Interest About Affymax (OTCMKTS:AFFY) StockAffymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Read More AFFY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFFY Stock News HeadlinesSeptember 25, 2023 | finance.yahoo.comJasper Therapeutics Appoints Herb Cross as Chief Financial OfficerSeptember 18, 2023 | markets.businessinsider.comAnaptysBio Announces Appointment of John Orwin as Chairman of the Board of DirectorsSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."June 7, 2023 | thestreet.com4 Biotech Stocks Under $5 to WatchMay 15, 2023 | thestreet.com10 Biotech Stocks on Clinical Trials WatchJanuary 19, 2023 | bizjournals.comWhy a UCSF vice chancellor is returning to the biotech industryJanuary 18, 2023 | marketwatch.comHinge Bio Expands Senior Management Team to Drive GEM-DIMER(TM) Programs to Clinical DevelopmentJanuary 18, 2023 | nz.finance.yahoo.comHinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical DevelopmentSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 14, 2022 | finanznachrichten.deTurn Biotechnologies, Inc.: Turn Biotechnologies launches eTurna delivery platform designed specifically to enable nucleic acid therapeuticsAugust 28, 2022 | reuters.comAFFY.PK - Affymax, Inc. | Stock Price & Latest News | ReutersAugust 25, 2022 | finance.yahoo.comFrontier Medicines Announces the Appointment of Seasoned Legal Executive Mark Dizon, J.D., as General CounselAugust 3, 2022 | investing.comEsso Thailand PCL F (ESSOf)August 3, 2022 | investing.comDialog Group Bhd (DIAL)July 30, 2022 | investing.comDPS Resources Bhd (DPSS)April 27, 2022 | marketwatch.comRenal Disease Treatment Market Size with New Growth Prospect By Top Key Players | Impact of COVID-19 PandemicMarch 27, 2022 | marketwatch.comRenal Disease Treatment Market Scope with New Growth Prospect By Top Key Players | Impact of COVID-19 PandemicSeptember 2, 2021 | ca.finance.yahoo.comArcutis Announces Appointment of Keith Leonard to Board of DirectorsApril 28, 2021 | ca.finance.yahoo.comDr. Mike Holfinger Joins Alladapt as Chief Technical OfficerJanuary 20, 2021 | apnews.comT-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A.December 29, 2020 | marketwatch.comPEGylated Protein Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027December 5, 2020 | apnews.comPipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical OperationsAugust 16, 2020 | markets.businessinsider.comAffymax IncShs - ProfileJuly 23, 2020 | www.marketwatch.comAffymax Inc.March 8, 2020 | www.bloomberg.comPomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and SettlementDecember 4, 2019 | finance.yahoo.comRubrYc Therapeutics Announces formation of its Scientific Advisory BoardJuly 11, 2019 | www.marketwatch.comAtreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General CounselSee More Headlines Receive AFFY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affymax and its competitors with MarketBeat's FREE daily newsletter. Email Address AFFY Company Calendar Today9/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolOTCMKTS:AFFY CUSIP00826A10 CIK1158223 Webwww.affymax.com Phone(650) 812-8700Fax650-424-0832Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta5.70 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Mark G. Thompson (Age 61)CFO & Sec. Comp: $97.49kMr. Jonathan M. Couchman (Age 53)CEO, Pres & Director Dr. Tracy J. Dunn Ph.D. (Age 60)J.D., VP of Intellectual Property & Legal Affairs Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors AFFY Stock - Frequently Asked Questions How have AFFY shares performed in 2023? Affymax's stock was trading at $0.0040 on January 1st, 2023. Since then, AFFY shares have increased by 5.0% and is now trading at $0.0042. View the best growth stocks for 2023 here. What other stocks do shareholders of Affymax own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affymax investors own include Golden Peak Minerals Inc.. (GRM), (MCPIQ) (MCPIQ), Bank of America (BAC), Boeing (BA), American Express (AXP), Aurinia Pharmaceuticals (AUPH), Actinium Pharmaceuticals (ATNM), Advanced Micro Devices (AMD), Alnylam Pharmaceuticals (ALNY) and Achaogen (AKAO). What is Affymax's stock symbol? Affymax trades on the OTCMKTS under the ticker symbol "AFFY." How do I buy shares of Affymax? Shares of AFFY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Affymax's stock price today? One share of AFFY stock can currently be purchased for approximately $0.00. How can I contact Affymax? Affymax's mailing address is 19200 STEVENS CREEK BOULEVARD SUITE 240, CUPERTINO CA, 95014. The official website for the company is www.affymax.com. The biopharmaceutical company can be reached via phone at (650) 812-8700, via email at investors@affymax.com, or via fax at 650-424-0832. This page (OTCMKTS:AFFY) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affymax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.